These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36808794)

  • 21. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
    Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
    Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity.
    Mahmoud HK; Farghaly TA; Abdulwahab HG; Al-Qurashi NT; Shaaban MR
    Eur J Med Chem; 2020 Dec; 208():112752. PubMed ID: 32947227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
    Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
    Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
    Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
    Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virtual screening and synthesis of new chemical scaffolds as VEGFR-2 kinase inhibitors.
    Elsayed MS; El-Araby ME; Serya RT; Abouzid KA
    Arzneimittelforschung; 2012 Dec; 62(12):554-60. PubMed ID: 23023518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
    Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations.
    Elrazaz EZ; Serya RAT; Ismail NSM; Albohy A; Abou El Ella DA; Abouzid KAM
    Bioorg Chem; 2021 Aug; 113():105019. PubMed ID: 34091286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.
    Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z
    Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fragment-based investigation of thiourea derivatives as VEGFR-2 inhibitors: a cross-validated approach of ligand-based and structure-based molecular modeling studies.
    Banerjee S; Kejriwal S; Ghosh B; Lanka G; Jha T; Adhikari N
    J Biomol Struct Dyn; 2024; 42(2):1047-1063. PubMed ID: 37029768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virtual Screening, Docking, and Designing of New VEGF Inhibitors as Anti-cancer Agents.
    Patel S; Singh VR; Suman AK; Jain S; Sen AK
    Curr Drug Discov Technol; 2024; 21(1):e101023222024. PubMed ID: 38629172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular docking aided machine learning for the identification of potential VEGFR inhibitors against renal cell carcinoma.
    Jerra VS; Ramachandran B; Shareef S; Carrillo-Bermejo A; Sundararaj R; Venkatesan S
    Med Oncol; 2024 Jul; 41(8):198. PubMed ID: 38981988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
    Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
    Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
    Khedr F; Ibrahim MK; Eissa IH; Abulkhair HS; El-Adl K
    Arch Pharm (Weinheim); 2021 Nov; 354(11):e2100201. PubMed ID: 34411344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors by Ligand-based Virtual High Throughput Screening.
    Selvam C; Mock CD; Mathew OP; Ranganna K; Thilagavathi R
    Mol Inform; 2020 Jul; 39(7):e1900150. PubMed ID: 32147949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular simulation studies to reveal the binding mechanisms of shikonin derivatives inhibiting VEGFR-2 kinase.
    Munni YA; Ali MC; Selsi NJ; Sultana M; Hossen M; Bipasha TH; Rahman M; Uddin MN; Hosen SMZ; Dash R
    Comput Biol Chem; 2021 Feb; 90():107414. PubMed ID: 33191109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors.
    Ai G; Tian C; Deng D; Fida G; Chen H; Ma Y; Ding L; Gu Y
    Anticancer Drugs; 2015 Apr; 26(4):399-409. PubMed ID: 25569705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.